权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

New Faculty Recruitment to the Indiana University Gene Therapy Program

印第安纳大学基因治疗项目新教师招聘

基本信息

批准号：
7935348
负责人：
KENNETH CORNETTA
金额：
$ 28.92万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2012-08-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): The Gene and Cell Therapy Program (GCTP) at Indiana University is a highly interactive group of investigators with a 15-year history of multi-departmental interaction and collaborative research. The program has a focus on the genetic manipulation of stem cells and is home to a world-class facility for the manufacture of clinical gene therapy products (funded by a NCRR construction grant). Indiana University is the NHLBI designated site for clinical lentiviral vector production through its Gene Therapy Resources Program. Indiana University is also the site of the National Gene Vector Biorepository funded by the NCRR/NIH. A NHLBI funded Program Project Grant (PI Dinauer) has facilitated the collaborations in the GCTP. Moreover, a NHLBI funded training grant in gene therapy has trained 5 pre-doctoral students and 22 post-doctoral fellows. An NIDDK training grant in hematopoiesis has trained 22 pre-doctoral students and 26 post-doctoral fellows. This P30 application will enhance this interactive group of gene and cell therapy experts while providing a proven, productive environment for the development of junior faculty. Specific Aim: The aim of this proposal is to fund recruitment of a junior faculty with expertise in gene transfer that can facilitate clinical trial and develop novel production methodology. The individual we seek to move to a tenure track position is Scott Witting, Ph.D. This P30 grant will enhance the Gene and Cell Therapy Program at Indiana University. Dr. Scott Witting will be hired as an Assistant Professor tenure track and develop an independent research program aimed at identifying the optimal, clinically relevant, gene transfer methodology for transduction of hematopoieitic and other stem cell products. This will facilitate clinical trials proposed by the GCTP members.

描述（由申请人提供）：印第安纳大学基因与细胞治疗项目 (GCTP) 是一个高度互动的研究小组，拥有 15 年多部门互动和协作研究的历史。该项目的重点是干细胞的基因操作，并拥有世界一流的临床基因治疗产品生产设施（由 NCRR 建设拨款资助）。印第安纳大学是 NHLBI 指定的通过其基因治疗资源计划进行临床慢病毒载体生产的场所。印第安纳大学也是由 NCRR/NIH 资助的国家基因载体生物储存库所在地。 NHLBI 资助的计划项目补助金 (PI Dinauer) 促进了 GCTP 中的合作。此外，NHLBI 资助的基因治疗培训基金已培训了 5 名博士前学生和 22 名博士后研究员。 NIDDK 造血学培训资助已培训了 22 名博士前学生和 26 名博士后研究员。该 P30 应用程序将增强基因和细胞治疗专家的互动小组，同时为初级教师的发展提供经过验证的、富有成效的环境。具体目标：该提案的目的是资助招聘具有基因转移专业知识的初级教师，以促进临床试验并开发新的生产方法。我们寻求晋升到终身教职的人是 Scott Witting 博士。这笔 P30 赠款将加强印第安纳大学的基因和细胞治疗项目。 Scott Witting 博士将被聘为助理教授终身教授，并开发一项独立研究计划，旨在确定用于转导造血和其他干细胞产品的最佳、临床相关的基因转移方法。这将促进 GCTP 成员提出的临床试验。